Home/ Applications/ Organoid & 3D Cell Culture

SeamlessBio · OLS OMNI Life Science · innoME GmbH

Organoid & 3D Cell Culture — Complete Setup from a Single Source

Exclusive DACH source for OrganoMedium™ (ISO 13485-certified organoid culture medium) and the OLS CERO 3D bioreactor. Tumour spheroids, intestinal, liver, brain, cardiac organoids — from research to GMP-adjacent workflows.

The only complete organoid setup in DACH — from one source.

No other supplier in DACH combines an exclusive ISO-certified organoid culture medium with a shear-force-free 3D bioreactor. This is our unique position.

OrganoMedium™ ensures your organoids grow consistently. CERO 3D ensures they survive long-term without handling stress.

OrganoMedium™
ISO 13485-certified · EU-manufactured · Exclusive DACH

CERO 3D
No shear forces · Scaffold-free · Long-term culture

OrganoMedium™ — Exclusive

ISO 9001 + ISO 13485-certified organoid culture medium. Chemically defined, EU-produced. Variants: Base, Brain, Intestinal, Liver, GMP-grade, Xeno-Free. Available exclusively via SeamlessBio/innoME in DACH.

CERO 3D — Gentle Bioreactor

OLS OMNI Life Science CERO 3D incubator/bioreactor for scaffold-free, shear-force-free long-term organoid culture. Tube-based rotation without agitation stress. Full environmental control.

Serum & Supplements

FBS Low Endotoxin, FBS Ultra Low IgG, BSA Fatty Acid-Free, FBS ES Cell Pre-Tested for iPSC-based organoids. Full SeamlessBio portfolio with batch reservation and EU origin.

Why standard media fail in organoid culture

Standard cell culture media — DMEM, RPMI, MEM — are formulated for 2D monolayer growth on flat surfaces. In 3D organoid culture, cells exist in spatial gradients, form tight junctions, develop polarity, and require specific growth factor environments to differentiate correctly. Standard media fail because they do not provide the Wnt pathway support, EGF/Noggin/R-Spondin signalling context, or defined albumin carrier required for organoid self-organisation.

Standard FBS adds a second problem: lot-to-lot variability in undefined growth factor content, endotoxin levels, and hormonal components introduces unpredictable variability in organoid formation efficiency, size distribution, and differentiation state. In drug testing assays on patient-derived organoids (PDOs), this variability directly affects drug response measurements — making data non-reproducible between experiments.

OrganoMedium™ solves both problems: a chemically defined formulation specifically optimised for 3D organoid growth, certified under ISO 9001 and ISO 13485, produced in the EU, available in organ-specific variants (Brain, Intestinal, Liver) and a Xeno-Free variant for 3R-aligned and clinical translation work. Exclusively distributed by SeamlessBio and innoME in the DACH region.

What you need for organoid culture

OrganoMedium™ Base — universal defined organoid medium
OrganoMedium™ Intestinal — ENR (EGF/Noggin/R-Spondin) compatible
OrganoMedium™ Brain — cerebral organoids, assembloids
OrganoMedium™ Liver — hepatic organoids, HGF-compatible
OrganoMedium™ Xeno-Free — 3R-compliant, clinical translation
OrganoMedium™ GMP — ISO 13485 full documentation
OLS CERO 3D — shear-free 3D bioreactor
FBS Low Endotoxin — standard spheroid media
FBS ES Cell Pre-Tested — iPSC-based organoids
BSA Fatty Acid-Free — serum-free basal supplement

OrganoMedium™ Product Line — ISO 13485-Certified Organoid Media

Exclusively distributed by SeamlessBio and innoME in the DACH region. EU-produced, ISO 9001 and ISO 13485 certified. Full COA, TSE/BSE documentation and lot reservation on request.

Universal

OrganoMedium™ Base

Chemically defined basal medium for all organoid types. Universal starting point for protocol development. No serum, no undefined components.

Neuro

OrganoMedium™ Brain

Optimised for cerebral organoids and assembloids. iPSC-based neuroectodermal differentiation. No serum — serum drives astrocyte differentiation and blocks neuronal specification.

OrganoMedium™ Intestinal

For intestinal organoids. Compatible with Wnt3a, R-Spondin, EGF, Noggin (ENR) supplementation. Patient-derived colorectal organoid support.

Liver

OrganoMedium™ Liver

For hepatic organoids and hepatospheres. HGF, EGF, dexamethasone compatible. Hepatocyte functionality maintained for DILI testing.

3R / Xeno-Free

OrganoMedium™ Xeno-Free

Fully animal-origin-free. 3R-compliant. For ethically aligned research, clinical translation, and GMP-adjacent workflows where no animal components are permitted.

GMP

OrganoMedium™ GMP

ISO 13485-certified production. Full regulatory documentation package: COA, TSE/BSE statement, lot traceability. For clinical-grade and IND-relevant organoid workflows.

Serum Selection by Organoid Type

Organoid Type	Application	Recommended Serum	Concentration & Note
Tumour spheroids (hanging drop / ULA)	Drug cytotoxicity, IC₅₀, cancer biology	FBS Low Endotoxin ≤5 EU/mL	2–5% — reduced serum promotes spheroid compaction and hypoxic core formation
Tumour spheroids — antibody assays (ADCC)	Anti-tumour mAb screening on 3D models	FBS Ultra Low IgG <5 µg/mL	2–5% — bovine IgG in standard FBS blocks Fc-receptor interactions on NK cells
Intestinal organoids	IBD, microbiome-gut interface, drug absorption	OrganoMedium™ Intestinal — serum-free	ENR defined conditions. rHSA or BSA Fatty Acid-Free as optional protein stabiliser.
Liver organoids / hepatospheres	DILI modelling, hepatotoxicity	OrganoMedium™ Liver or FBS Low Endotoxin ≤5 EU/mL	2–5% for HepaRG spheroids. Serum-free preferred for primary human hepatocytes.
Brain / cerebral organoids	Neurological disease, neurotoxicity	OrganoMedium™ Brain — serum-free	Serum drives astrocyte differentiation — serum-free N2/B27 or OrganoMedium™ Brain required.
Pancreatic / colorectal PDOs	Personalised oncology drug testing	OrganoMedium™ Base — serum-free	Serum-free preferred — FBS undefined signals compromise PDO engraftment reproducibility.
iPSC-based organoids	Cardiac, neural, intestinal organoids from iPSC	FBS ES Cell Pre-Tested (early EB stage) → OrganoMedium™	ES Cell Pre-Tested for EB formation; serum-free OrganoMedium™ for directed differentiation.
Cardiac spheroids	Cardiotoxicity testing	FBS Low Endotoxin ≤5 EU/mL — 2% maintenance	Low serum maintains cardiomyocyte contractility measurements — high serum masks force generation.

OrganoMedium™ vs Standard Media — What Makes It Different

Feature	OrganoMedium™	Standard FBS-based Media	Matrigel (matrix only)
Defined composition	✓ Fully defined	✗ Undefined	✗ Undefined
Organoid-specific formulation	✓ Exclusive	✗ General purpose	Matrix only, no medium
ISO 13485 certified	✓	✗	✗
ISO 9001 certified	✓	Rarely	✗
EU production	✓	Mostly US	✗ US only
Animal-origin-free option	✓ Xeno-Free variant	✗	✗
TSE/BSE documentation	✓ Complete	Partial	✗
Lot reservation	✓ On request	Rarely	✗
Batch-to-batch consistency	✓ High	✗ Variable	✗ Variable

Frequently Asked Questions

What is OrganoMedium™ and why is it different from standard DMEM or mTeSR1?

OrganoMedium™ is a chemically defined organoid culture medium formulated specifically for 3D organoid growth, expansion and differentiation — not for 2D monolayer culture. Standard media like DMEM provide only basic nutrients and buffering without the Wnt pathway support, EGF/Noggin/R-Spondin signalling context, and defined albumin carrier that organoids require for self-organisation. mTeSR1 and similar iPSC media are formulated for 2D iPSC expansion — they do not provide the differentiation signalling context required for organoid formation. OrganoMedium™ is also certified under ISO 9001 and ISO 13485, which no standard commercial media are.

Is OrganoMedium™ a Matrigel replacement?

OrganoMedium™ is a culture medium, not a matrix replacement. Matrigel is an extracellular matrix scaffold — OrganoMedium™ optimises the nutrient supply and growth signalling environment around and within that matrix. The two are complementary. OrganoMedium™ can be used alongside Matrigel, defined matrix alternatives (Cultrex UltiMatrix, BME Type 2), or in some scaffold-free formats (ULA, CERO 3D bioreactor). For matrix-free culture we recommend combining OrganoMedium™ with a compatible synthetic scaffold.

Why is serum concentration reduced to 2–5% in spheroid and organoid culture?

High serum concentrations (10%) in ultra-low attachment conditions promote cell survival but reduce spheroid compaction — cells remain loosely aggregated rather than forming tight, physiologically relevant structures with cell-cell contacts and a hypoxic core. Reducing serum to 1–5% promotes tight spheroid formation that better replicates the tumour microenvironment and solid tissue architecture. For drug testing on spheroids, compact structures with a necrotic or quiescent core more accurately predict drug penetration and resistance mechanisms than loose aggregates formed at high serum.

Is OrganoMedium™ available in a GMP-grade version?

Yes. OrganoMedium™ GMP is produced under ISO 13485 with full GMP-adjacent documentation: COA with lot number, TSE/BSE-free statement, Certificate of Origin (EU production), change control documentation, and extended stability data. This is the appropriate grade for IND-relevant organoid assays, clinical translation studies, and GMP process development where regulatory agencies will scrutinise raw material quality. Lot reservation is available for GMP-grade OrganoMedium™ to ensure process consistency across extended study periods.

Which organoid types is the CERO 3D bioreactor best suited for?

The OLS CERO 3D is particularly well-suited for: iPSC-derived organoids (cardiac, cerebral, intestinal) requiring long-term scaffold-free culture; tumour spheroid generation at scale for drug testing; stem cell expansion for organoid seeding; and any 3D culture requiring extended culture periods (weeks to months) without embedding substrate. The CERO 3D uses a tube-rotation mechanism that eliminates shear forces — the primary cause of organoid fragmentation in conventional spinner flasks — while maintaining full environmental control (temperature, CO₂, humidity).

Where is OrganoMedium™ produced and who distributes it in DACH?

OrganoMedium™ is produced by SeamlessBio in the European Union with full traceability, TSE/BSE documentation and ISO 9001/ISO 13485 certification. In the DACH region, OrganoMedium™ is available exclusively through SeamlessBio (seamlessbio.de) and innoME (innome.de) under an exclusive distribution agreement with OLS OMNI Life Science. It is not available through general distributors or online marketplaces.

← All Application Guides Overview

Request OrganoMedium™ Samples

Free OrganoMedium™ samples available on request. ISO documentation, COA and TSE/BSE statements provided.
Email: info@seamlessbio.de | +49 851 37932226